Wall Street Zen Downgrades NeuroSense Therapeutics (NASDAQ:NRSN) to Sell

NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other research analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 8th. Zacks Research upgraded NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a report on Monday, November 24th. Finally, Noble Financial raised NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

NeuroSense Therapeutics Price Performance

NRSN stock opened at $0.89 on Friday. The company’s fifty day moving average price is $1.10 and its 200-day moving average price is $1.43. NeuroSense Therapeutics has a one year low of $0.81 and a one year high of $2.60.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC raised its position in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the period. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Finally, Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the 3rd quarter valued at approximately $26,000. 1.04% of the stock is owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.